ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC

For patients with muscle-invasive urothelial carcinoma (MIUC), detectable ctDNA after surgery is a marker of poor prognosis and of response to the immunotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news